RIPK3 Inhibitors for the Treatment of Inflammatory and Degenerative Conditions
Receptor-interacting protein kinase 3 (RIPK3) is a multi-functional protein involved in cell death pathways in various tissues. We now have developed a panel of new RIPK3 inhibitors, termed the UH15 series, which potently and specifically inhibit RIPK3-driven necroptosis. UH15 analogs have been identified that block necroptosis but do so without toxicity. These UH15-based molecules can be used to treat inflammatory and degenerative conditions, including, but not limited to, sepsis, brain trauma, acute kidney injuries, lung injury associated with influenza (IAV) infection, and atherosclerosis.
Patents
  • 62/848,648
Case ID
2019-017
Inventor
Greg Cuny
Associate Professor, College of Pharmacy